Torthaí cuardaigh - Catherine E. Chaillan Huntington
- 1 - 2 toradh as 2 á dtaispeáint
-
1
Tozorakimab (MEDI3506): an anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunction de réir Elizabeth England, D. Gareth Rees, Ian C. Scott, Sara Carmen, Denice T. Y. Chan, Catherine E. Chaillan Huntington, Kirsty F. Houslay, Teodor Erngren, Mark Penney, Jayesh B. Majithiya, Laura Rapley, Dorothy A. Sims, Claire Hollins, Elizabeth C. Hinchy, Martin Strain, Benjamin Kemp, Dominic J. Corkill, Richard May, Katherine A. Vousden, Robin Butler, Tomas Mustelin, Tristan J. Vaughan, David C. Lowe, Caroline Colley, E. Suzanne Cohen
Foilsithe / Cruthaithe 2023Artigo -
2
Oxidation of the alarmin IL-33 regulates ST2-dependent inflammation de réir E. Suzanne Cohen, Ian C. Scott, Jayesh B. Majithiya, Laura Rapley, Benjamin Kemp, Elizabeth England, D. Gareth Rees, Catherine L. Overed‐Sayer, Joanne Woods, Nicholas J. Bond, Christel Séguy Veyssier, Kevin J. Embrey, Dorothy A. Sims, Michael Snaith, Katherine A. Vousden, Martin Strain, Denice T. Y. Chan, Sara Carmen, Catherine E. Chaillan Huntington, Liz Flavell, Jianqing Xu, Bojana Popovic, Christopher E. Brightling, Tristan J. Vaughan, Robin Butler, David C. Lowe, Daniel R. Higazi, Dominic J. Corkill, Richard May, Matthew A. Sleeman, Tomas Mustelin
Foilsithe / Cruthaithe 2015Artigo